- Subjects must have participated and completed the previous Pegvisomant studies or have
shown to be unresponsive to other conventional therapies
- ALT/AST>3 times the ULN or have hepatic disease
- have severe visual field loss, cranial nerve palsies or intracranial HTN that requires
surgery to decompress the tumor
- unwilling to self-administer the medication.